Nkarta (NKTX)
(Delayed Data from NSDQ)
$6.65 USD
-0.92 (-12.15%)
Updated Jul 18, 2024 04:00 PM ET
After-Market: $6.64 -0.01 (-0.15%) 7:46 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Nkarta, Inc. (NKTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$17.86 | $25.00 | $13.00 | 135.93% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Nkarta, Inc. comes to $17.86. The forecasts range from a low of $13.00 to a high of $25.00. The average price target represents an increase of 135.93% from the last closing price of $7.57.
Analyst Price Targets (7 )
Broker Rating
Nkarta, Inc. currently has an average brokerage recommendation (ABR) of 1.22 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.22 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, seven are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 77.78% and 22.22% of all recommendations. A month ago, Strong Buy made up 77.78%, while Buy represented 22.22%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.22 | 1.22 | 1.22 | 1.22 | 1.22 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/28/2024 | Needham & Company | Gil J Blum | Moderate Buy | Moderate Buy |
6/27/2024 | H.C. Wainwright & Co. | Emily Bodnar | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Yaron Werber | Strong Buy | Strong Buy |
3/26/2024 | Canaccord Genuity | William Maughan | Strong Buy | Strong Buy |
3/22/2024 | William Blair | Sami Corwin | Strong Buy | Strong Buy |
3/22/2024 | Raymond James | Laura Prendergast | Strong Buy | Moderate Buy |
3/5/2024 | Mizuho SecuritiesUSA | Salim Syed | Strong Buy | Strong Buy |
3/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/18/2024 | SVB Securities | Daina M Graybosch | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.22 |
ABR (Last week) | 1.22 |
# of Recs in ABR | 9 |
Average Target Price | $17.86 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 70 of 252 |
Current Quarter EPS Est: | -0.49 |